Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Bevacizumab in Cancer Patients
NCT00109057Phase 2Completed
- Sponsor
- Genentech
- Start
- Feb 1998
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in cancer, sponsored by Genentech. Primary endpoint: Safety and Tolerability. Started Feb 1998; status: completed.
02
Drugs
bevacizumab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT00109057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109057.